Exagen Inc (XGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Exagen Inc (XGN) has a cash flow conversion efficiency ratio of -0.722x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.42 Million) by net assets ($14.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Exagen Inc to measure how many days the company can operate on defensive assets alone.
Exagen Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Exagen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Exagen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Exagen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EcoFirst Consolidated Bhd
KLSE:3557
|
0.008x |
|
SUI Group Holdings Limited
NASDAQ:SUIG
|
-0.018x |
|
Orian Sh.M. Ltd
TA:ORIN
|
0.107x |
|
Kalaris Therapeutics, Inc.
NASDAQ:KLRS
|
-0.195x |
|
Lemonsoft Oyj
HE:LEMON
|
0.093x |
|
MLRN Projects and Trade Ltd
TA:MLRN
|
-0.419x |
|
Active Biotech AB
ST:ACTI
|
-1.600x |
|
LITHIUM IONIC CORP.
F:H3N
|
N/A |
Annual Cash Flow Conversion Efficiency for Exagen Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Exagen Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see XGN stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.45 Million | $-13.62 Million | -0.781x | +43.90% |
| 2024-12-31 | $9.54 Million | $-13.28 Million | -1.392x | -118.42% |
| 2023-12-31 | $22.69 Million | $-14.46 Million | -0.637x | +15.82% |
| 2022-12-31 | $42.46 Million | $-32.14 Million | -0.757x | -217.23% |
| 2021-12-31 | $84.94 Million | $-20.27 Million | -0.239x | +29.11% |
| 2020-12-31 | $41.84 Million | $-14.08 Million | -0.337x | -92.94% |
| 2019-12-31 | $55.66 Million | $-9.71 Million | -0.174x | -112.63% |
| 2018-12-31 | $-6.73 Million | $-9.30 Million | 1.381x | -41.59% |
| 2017-12-31 | $-4.64 Million | $-10.97 Million | 2.365x | +340.77% |
| 2015-12-31 | $-22.18 Million | $-11.90 Million | 0.537x | -30.00% |
| 2014-12-31 | $-14.06 Million | $-10.77 Million | 0.766x | +105.04% |
| 2013-12-31 | $451.00K | $-6.87 Million | -15.222x | -881.67% |
| 2012-12-31 | $4.82 Million | $-7.48 Million | -1.551x | -- |
About Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead test… Read more